Literature DB >> 3219226

Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer.

J Andersen1, H S Poulsen.   

Abstract

Treatment of metastatic breast cancer based on the estrogen receptor content (ER) of the primary tumor builds on the assumption that the ER status of the primary tumor and the metastases are largely equal. Studies addressing this question have used ligand-binding assays for ER determination and have consequently been subject to the limitations of this technique. Reported disparity rates have been 20%. In order to avoid some of these limitations, we used an immunohistochemical assay in paraffin-embedded tissue. Among a total of 92 examined regional lymph node metastases, ER status was equal with that of their 37 primaries in 84 cases (91%). Semiquantified ER content was significantly correlated in primary tumor and the metastases (r = 0.67, p less than 0.001). Among a total of 51 distant metastases, equal ER status was found in 44 (86%) cases and a quantitative relationship could not be established. Disparities can be due to methodological errors in the histochemical assay or tumor heterogeneity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3219226     DOI: 10.3109/02841868809091782

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

1.  Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer.

Authors:  María Fernanda García; Salomé González-Reyes; Luis Ovidio González; Sara Junquera; Nana Berdize; José Manuel Del Casar; María Medina; Francisco José Vizoso
Journal:  Int J Exp Pathol       Date:  2010-04-20       Impact factor: 1.925

2.  Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer.

Authors:  Huai-Lu Chang; Yu-Jen Cheng; Chung-Kuang Su; Meng-Chih Chen; Fu-Hsin Chang; Fu-Gong Lin; Li-Feng Liu; Shyng-Shiou F Yuan; Ming-Chih Chou; Chien-Fu Huang; Chi-Chiang Yang
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

3.  Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study.

Authors:  Janina Kulka; Borbála Székely; Lilla V Lukács; Orsolya Kiss; Anna-Mária Tőkés; Eszter Vincze; Eszter Turányi; János Fillinger; Zoltán Hanzély; Gabriella Arató; Miklós Szendrői; Balázs Győrffy; A Marcell Szász
Journal:  J Histochem Cytochem       Date:  2016-04       Impact factor: 2.479

4.  Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.

Authors:  Giuseppe Bogina; Laura Bortesi; Marcella Marconi; Marco Venturini; Gianluigi Lunardi; Francesca Coati; Alberto Massocco; Erminia Manfrin; Cristina Pegoraro; Giuseppe Zamboni
Journal:  Virchows Arch       Date:  2011-06-04       Impact factor: 4.064

5.  Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer.

Authors:  Y Umekita; Y Sagara; H Yoshida
Journal:  Jpn J Cancer Res       Date:  1998-01

6.  On the way to specifically targeting minimal residual disease?

Authors:  Gerhard Gebauer
Journal:  Breast Cancer Res       Date:  2008-10-07       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.